Compounded with
Semaglutide
Not verified in the bound record.
Tirzepatide
Not verified in the bound record.
Product evidence does not establish current availability.
Pharmacy evidence record · researched 2026-08-20
Triad Rx
Triad Rx, Inc.
6 citations5 action records5 explicit unknowns
Locations in the source record
- 26258 Pollard Rd, Daphne, AL 36526
Services named by sources
- Nonsterile compounding
- Wellness medications
- Hormone replacement
- Sexual dysfunction
- Hair loss
- Dermatology
- Weight-loss medications
Regulatory compliance
503 pathway evidence
A pathway label describes which federal rules apply — it is not a quality claim.
Section 503A
Source-backed pathway evidence
FDA's action records identify Triad as a 503A facility; FDA closeout says the firm no longer produced sterile drugs as of 2023.
Section 503B
Not conclusively established
not found in current fda registry check
Telehealth providers
No provider relationship is verified in the bound sources.
Clinic Scout links a provider only when an explicit source names the relationship.
Regulatory history
Actions stay dated and bounded.
FDA warning/closeout, Form 483, state-referral/current-503B, Alabama board and DOJ sources were checked. The referral was found; no Alabama final board order was recovered.
U.S. Food and Drug Administration · 2017-07-21
Form FDA 483
issuedU.S. Food and Drug Administration · 2019-02-05
Warning Letter
FDA cited section 503A-condition failures and insanitary sterile-compounding practices; closeout states the violations appeared adequately addressed and Triad no longer produced sterile drugs.
closed_out_2023-05-03U.S. Department of Justice · 2022-10-12
Civil False Claims Act settlement
Triad settled allegations that a prescription-sale arrangement constituted an illegal kickback. The settlement resolved allegations and was not a determination of liability.
Status not statedU.S. Food and Drug Administration · 2022-12-08
Form FDA 483
FDA cited inadequate cleaning/deactivation controls for hazardous drug production.
Status not statedU.S. Food and Drug Administration · 2024-05-03
State referral letter
FDA referred poor-practice concerns for state follow-up.
Status not statedWhat remains unverified
- Semaglutide relevance
- Tirzepatide relevance
- Exact states licensed
- Current Alabama license status
- Alabama disposition after 2024 referral
Patient reviews
Share your experience for moderationNo Clinic Scout patient reviews are published for this pharmacy. Submissions go through manual moderation before anything appears here.
What this record verifies for you
6 evidence dimensions carry dated, source-backed verification.
Each line traces to a citation in the source list below — read the exact captured wording before relying on it.
- dated source ledger: 6 first-party/regulator citations with URL, accessed date, and exact supporting quote.
- legal entity provenance: Legal entity recorded as Triad Rx, Inc. with status verified_fda_and_first_party.
- regulator verified state evidence: 1 regulator-verified state record(s) preserved with field-level provenance.
- regulatory action timeline: 5 dated regulatory/action record(s) with bounded summaries and regulator citations.
- 503 status provenance: 503A/503B fields preserve pathway, source status, and current-versus-historical limits from the bound research.
- transparent unknowns: 5 unresolved field(s) are explicitly named and prevented from rendering as facts.
No superiority claim is made for review volume, ratings, or patient sentiment.
Sources and exact captured wording
- first_party · accessed 2026-08-20
Triad Rx has been serving the community of Daphne since 2012. We are licensed in over 45 States and ship nationwide ... weight loss medications
- fda · accessed 2026-08-20
Your firm produced drug products that do not meet the conditions of section 503A ... Partially stoppered vials of product intended to be sterile were observed to be exposed to lower than ISO 5 quality air
- fda · accessed 2026-08-20
it appears that you have adequately addressed the violations contained in this warning letter ... your firm no longer produces sterile drug products
- fda · accessed 2026-08-20
The purpose of this letter is to refer to you, the Alabama State Board of Pharmacy (BOP) for appropriate follow up ... FDA's concerns about poor practices observed during an FDA inspection
- other_regulator · accessed 2026-08-20
TRIAD Rx, Inc. will pay $166,547 ... The government alleged that this arrangement constituted an illegal kickback
- fda · accessed 2026-08-20
You produced hazardous diugs without providing adequate cleaning of work surfaces and cleaning of utensils to prevent cross-contamination. Specifically, there is no deactivating agent used to clean work surfaces, utensils ... in between production of different hazardous diug products.
Questions readers ask
Is Triad Rx legit?
GLP Clinic Scout does not issue a blanket legitimacy verdict. This research record preserves 6 dated first-party or regulator citation(s), 5 regulatory/action record(s), and 5 explicitly unresolved field(s). Review the cited evidence and current license status before making a decision.